Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17175| Title: | Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). | Austin Authors: | Chia, Puey Ling ;John, Thomas | Affiliation: | School of Cancer Medicine, La Trobe University, Victoria, Australia Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Heidelberg, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia |
Issue Date: | Jun-2016 | Publication information: | Journal of immunotherapy 2016; 39(5): 202-204 | Abstract: | Immunomodulatory agents that target PD-1 and its ligand (PD-L1) are being increasingly used in the management of lung cancer. Potential immune-related adverse events include dermatological complications which mostly are of low grade severity. The use of immune checkpoint inhibitors may lead to the exacerbation of autoimmune conditions. We report a case of a documented psoriasis flare with anti-PD-1 treatment for lung cancer. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/17175 | DOI: | 10.1097/CJI.0000000000000121 | Journal: | Journal of immunotherapy | PubMed URL: | 27163740 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/27163740 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.